Research programme: Alzheimer's disease therapeutics - ENKAM

Drug Profile

Research programme: Alzheimer's disease therapeutics - ENKAM

Alternative Names: FGL-S

Latest Information Update: 13 Dec 2011

Price : $50

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders

Most Recent Events

  • 08 Dec 2011 Preclinical trials in Cognition disorders in Denmark (Parenteral)
  • 08 Dec 2011 FGLS is still in Preclinical trials for Alzheimer's disease in Denmark
  • 19 May 2009 Preclinical trials in Alzheimer's disease in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top